A clinical failure from Verona Pharma (VRP) sent shares in the drug developer crashing further. A three-day second-phase trial – of a potential respiratory drug known as RPL554 – saw it administered to patients on top of an inhaler commonly used in the treatment of chronic obstructive pulmonary disease (COPD).
IC TIP:
Hold
at
80p
However, the company said patients failed to show a statistical improvement, despite adjusting for doses and timeframes. However, chief executive Jan-Anders Karlsson said the data collected gave the company “clarity” for any further development of the drug.
